FDA Person
Office of Regulatory AffairsBrian D. Nicholson
View detailed information about Brian D. Nicholson, including compliance records, violations, and related data.
Person Profile
Comprehensive profile of Brian D. Nicholson, including their role, qualifications, and regulatory activities.
Recent Records (36)
Page 1 of 2483 - Unknown Company
483
483 - Apollo Care, LLC
483
483 - Akom Pharmaceuticals, Inc.
483
483 - Option Care Enterprises
483
483 - Axium Healthcare Pharmacy dba Balanced Solutions Compounding
483
483 - Bella Pharmaceuticals, Inc.
483
483 - Fresenius Kabi USA LLC
483
483 - Morton Grove Pharmaceuticals, Inc.
483
WARNING_LETTER - Bell International Laboratories, Inc.
WARNING_LETTER
STATE_REFERRAL_LETTER - SNF Holdings, LLC dba Vios Compounding
STATE_REFERRAL_LETTER
483 - Akom Pharmaceuticals, Inc.
483
483 - Antares Pharma, Inc
483
483 - Dental Technologies, Inc.
483
EIR - Fresenius Kabi USA, LLC
EIR
483 - Japan Food Research Laboratories, Chitose Laboratory
483
483 - Grain Processing Corporation
483
483 - Washington University School of Medicine
483
483 - Sucampo Pharma, LLC
483
483 - Japan Food Research Laboratories, Chitose Laboratory
483
483 - Micro Measurement Laboratories, Inc.
483
Showing 1-20 of 36 records
Related People (5)
Related Office
Person Information
Name
Brian D. Nicholson
Role
Regulatory Personnel
ID: 83ea13dd-6753-468a-a0ca-19e3ef4158dd
Get More Insights
Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.
1.5M+ regulatory data points
Real-time compliance monitoring
Interactive analytics dashboard
Looking for more people? Our platform provides access to thousands of FDA people with advanced search and filtering capabilities.
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Stay ahead of FDA enforcement
New KeyPedia insights, webinars, and regulatory analysis — straight to your inbox. Unsubscribe anytime.